BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, December 10, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 1, 2014

View Archived Issues

SBI Pharmaceuticals and the University of Oxford to begin phase II trial of 5-ALA

Read More

Theraclone forms agreement with Gilead Sciences for neutralizing HIV antibodies

Read More

Jenken completes sale of assets to TaiwanJ

Read More

Nanosyn establishes research services agreement with Forma Therapeutics

Read More

Cloud Pharmaceuticals receives grant for in silico drug discovery

Read More

Rosetta Genomics enters two microRNA collaborations

Read More

Proteostasis Therapeutics achieves preclinical milestone in Biogen Idec collaboration

Read More

Advaxis and University of Pennsylvania modify Listeria technology agreement

Read More

Cynata engages University of Wisconsin-Madison to develop stem cell preservation technology

Read More

Phase II results presented for siRNA drug for the prophylaxis of DGF

Read More

Mitsubishi Tanabe Pharma recaps developments of first quarter of fiscal 2014

Read More

Prevention of ischemia/reperfusion injury by blockade of the NF-kappa-B pathway with SPA-0355

Read More

Eleven Biotherapeutics patents new anti-PCSK9 MAbs

Read More

New podophyllotoxin derivatives patented by Advanomics for cancer

Read More

New inhibitors of HCV NS5B polymerase disclosed by Bristol-Myers Squibb

Read More

Bristol-Myers Squibb patents novel ROCK inhibitors

Read More

Sumitomo Dainippon Pharma reviews progress of first quarter of fiscal 2014

Read More

Flexion signs licensing agreement with SwRI for microsphere manufacturing technologies

Read More

Redbiotec and GE Healthcare collaborate to develop novel manufacture process for CMV vaccine

Read More

EMA accepts Eisai's request for accelerated assessment of lenvatinib

Read More

Meda to acquire Rottapharm

Read More

FDA advisory committee recommends approval of HyQvia for primary immunodeficiency

Read More

First-in-human trial results for anti-CD40 MAb CFZ-533 as an immunosuppressant

Read More

Taiho Pharmaceutical terminates phase III trial of TSU-68 in hepatocellular carcinoma

Read More

CytoDyn reports interim data from phase IIb trial of PRO-140 in patients with HIV

Read More

Intravenous posaconazole recommended for approval in E.U.

Read More

Asahi Kasei Pharma files regulatory submission for Xiaflex in Japan

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 9, 2025.
  • Red dollar sign under microscope

    Medline plans record-setting $5.37B IPO

    BioWorld MedTech
    Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
  • 3D rendering of prion structure

    Epigenetic technology could eliminate misfolded prion proteins

    BioWorld Science
    The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
  • Novo Nordisk semaglutide pill

    CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

    BioWorld
    A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing